drugset / Trial / NCT06241105
Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer
Phase 2
Unknown
69 enrolled
Peking Union Medical College Hospital
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · collabThe Second Affiliated Hospital of Dalian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators propose to initiate a study assessing the efficacy and safety of a lower initial dosage of lenvatinib combined with toripalimab in patients suffering from platinum-resistant recurrent ovarian cancer. The objective of this research is to offer a novel therapeutic approach for patients battling relapsed ovarian cancer with platinum resistance.
Timeline
- Start
- 2023-02-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |